Sture Lindegren

Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of ²¹¹At-MX35 F(ab′)₂—A Phase I Study

Håkan Andersson, Elin Cederkrantz, Tom Bäck et al. · Journal of Nuclear Medicine · 2009 · 288 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields

Sture Lindegren, Tom Bäck, Holger Jensen · Applied Radiation and Isotopes · 2001 · 150 citations

Natural Sciences, Chemical Engineering, Chemistry +5

Direct Procedure for the Production of²¹¹At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate

Sture Lindegren, Sofia H.L. Frost, Tom Bäck et al. · Journal of Nuclear Medicine · 2008 · 79 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Intraperitoneal α-Emitting Radioimmunotherapy with²¹¹At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

Andreas Hallqvist, Karin Bergmark, Tom Bäck et al. · Journal of Nuclear Medicine · 2019 · 73 citations · Full text

Medicine, Immunology, Oncology +17

Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice

Stig Palm, Tom Bäck, Ingela Claesson et al. · International Journal of Radiation Oncology*Biology*Physics · 2007 · 72 citations · Full text

Medicine, Cancer Biology, Oncology +17